Developing a novel non-oncology small molecule drug involves much more than discovering a promising compound. Before advancing to clinical trials, regulatory authorities require comprehensive safety data to support an Investigational New Drug (IND) application. For non-oncology indications, this data must be generated through a sequence of preclinical studies—each designed with a specific purpose, interdependent timelines, and clearly defined regulatory expectations.
This guide outlines the essential study categories needed for IND submission, detailing their objectives, required endpoints, and how they contribute to the safe and efficient transition to human trials.
1. ADME Studies: Understanding How the Drug Moves Through the Body
Absorption, Distribution, Metabolism, and Excretion (ADME) studies help determine how your compound behaves in biological systems. These insights are foundational for selecting species for toxicity testing, determining dosing frequency, and projecting human pharmacokinetics.
Key ADME studies include:
- In vitro metabolic stability (e.g., microsomes or hepatocytes).
- Plasma protein binding and blood-to-plasma partitioning.
- In vivo pharmacokinetics in rodent and non-rodent models.
- Metabolite identification (Met ID) studies to evaluate species differences and human relevance.
- Drug-drug interaction potential: CYP inhibition/induction and transporter assays.
When are Met ID studies needed?
Typically, early in development—especially before GLP tox—when evaluating if major or disproportionate human metabolites require additional safety coverage.
2. Dose Range Finding (DRF) & Non-GLP Tolerability Studies: Optimizing Safety Before GLP
These studies are conducted to evaluate how animals tolerate different doses of the compound before starting GLP-compliant toxicology. A DRF study is particularly important because it identifies appropriate dose levels and potential target organ effects, helping to inform the design of repeat-dose GLP studies.
Key non-GLP and DRF studies include:
- DRF studies (often 7–14 days) in both rodent and non-rodent species.
- Single-dose and escalating-dose tolerability assessments.
- Repeat-dose tolerability (3- to 7-day studies).
- Formulation/route of administration evaluations.
- Limited clinical pathology, body weights, and gross necropsy.
- Preliminary histopathology, especially if adverse effects are noted.
These studies reduce risk and cost by revealing early toxicity, avoiding dose missteps in GLP studies, and informing species selection.
3. GLP Toxicology Studies: Establishing the Safety Profile
GLP (Good Laboratory Practice) toxicology studies are the regulatory cornerstone for evaluating drug safety prior to clinical trials. These define the No Observed Adverse Effect Level (NOAEL) and help estimate a safe starting dose in humans.
GLP studies include:
- 28 repeat-dose toxicity studies in rodents and non-rodents.
- Toxicokinetics (TK) to correlate systemic exposure with effects.
- Clinical pathology (hematology, chemistry, urinalysis).
- Gross pathology and organ weights.
- Comprehensive histopathology of all major tissues.
- Optional recovery groups to assess reversibility of findings.
4. Safety Pharmacology: Evaluating Key Physiological Systems
According to ICH S7A/S7B, safety pharmacology studies are required to evaluate whether your compound interferes with essential functions such as heart rate, respiration, or nervous system activity.
Typical safety pharmacology studies:
- hERG assay (in vitro ion channel inhibition).
- Cardiovascular telemetry studies in conscious non-rodents.
- Respiratory function via plethysmography in rodents.
- CNS safety via a functional observation battery (FOB).
- Follow-up renal or GI studies depending on compound class.
5. Bioanalytical Method Validation: Supporting Reliable Data
All pharmacokinetic and toxicokinetic data must be generated using validated bioanalytical methods to ensure accuracy and reproducibility.
Validation activities include:
- LC-MS/MS method development and validation (matrix-specific).
- Accuracy, precision, linearity, and lower limit of quantification.
- Stability assessments (short/long-term, freeze-thaw, benchtop).
- Matrix effect evaluations and selectivity testing.
- Partial validations for additional species or matrices.
6. Pathology: Interpreting the Biological Response
Pathology provides key interpretation of adverse findings and characterizes how tissues and organs respond to drug exposure.
Pathology studies include:
- Gross necropsy during and at the end of dosing.
- Organ weight analysis.
- Microscopic histopathology on major organs and any tissues showing abnormalities.
- Optional special stains or IHC for mechanistic insights or biomarker tracking.
7. IND-Enabling Support and Documentation
Once all required studies are complete, the focus turns to organizing the data into a structured IND submission that supports initiation of clinical trials.
Support includes:
- IND summary documentation for Modules 2 and 4.
- Study synopses for FDA/EMA review.
- Final GLP study reports and bioanalytical validations.
- Justifications for species selection and NOAEL derivation.
- Dosing rationale and safety margin calculations.
Your Development Journey: Integrated, Not Isolated
Each study is not an isolated task, but rather a step in a connected journey. By taking a strategic approach to how ADME, DRF, toxicology, and safety data are generated, you can improve regulatory clarity and development efficiency.
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”
